Pemmaraju N, et al. Blood (2016) cited as Ref 558 in DOI: 10.1038/s41392-020-0110-5 (Q9821)
Revision as of 22:04, 20 May 2020 by Admin (talk | contribs) (Created claim: Property:P93: Results from phase 2 trial ongoing expansion stage of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), #quickstatements; #temporary_batch_1590010982689)
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
In more languages
Configure| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Pemmaraju N, et al. Blood (2016) cited as Ref 558 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Results from phase 2 trial ongoing expansion stage of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) (English)
